Repligen (RGEN) Projected to Post Earnings on Tuesday

Repligen (NASDAQ:RGEN) is projected to announce its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect the company to announce earnings of $0.38 per share and revenue of $192.0850 million for the quarter. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:00 AM ET.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $197.91 million during the quarter, compared to the consensus estimate of $192.23 million. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The business’s revenue was up 18.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.44 EPS. On average, analysts expect Repligen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $117.20 on Monday. The company has a 50 day simple moving average of $121.56 and a 200-day simple moving average of $144.68. The company has a market capitalization of $6.61 billion, a P/E ratio of 137.88, a P/E/G ratio of 2.28 and a beta of 1.09. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.12. Repligen has a 1 year low of $109.50 and a 1 year high of $175.77.

Institutional Trading of Repligen

Several institutional investors have recently added to or reduced their stakes in the stock. Headlands Technologies LLC purchased a new position in Repligen in the 2nd quarter valued at approximately $353,000. Armistice Capital LLC purchased a new position in Repligen in the 3rd quarter valued at approximately $316,000. Brooklyn Investment Group purchased a new position in Repligen in the 4th quarter valued at approximately $298,000. Oxford Asset Management LLP boosted its position in Repligen by 25.9% in the 2nd quarter. Oxford Asset Management LLP now owns 2,182 shares of the biotechnology company’s stock valued at $271,000 after buying an additional 449 shares during the period. Finally, Wealthspire Advisors LLC boosted its position in Repligen by 1,169.8% in the 4th quarter. Wealthspire Advisors LLC now owns 1,600 shares of the biotechnology company’s stock valued at $262,000 after buying an additional 1,474 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on RGEN shares. Canaccord Genuity Group cut their price target on shares of Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a report on Monday, April 20th. Rothschild & Co Redburn set a $160.00 price target on shares of Repligen and gave the stock a “buy” rating in a report on Friday, April 17th. Roth Mkm started coverage on shares of Repligen in a report on Friday, April 17th. They set a “buy” rating and a $160.00 price target for the company. Wall Street Zen downgraded shares of Repligen from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Barclays cut their price target on shares of Repligen from $175.00 to $145.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $170.25.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.